Venlo, The Netherlands, January 31, 2018 – QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has passed a resolution to exercise the authorization granted by the General Meeting of Shareholders on June 21, 2017, and to purchase shares in the Company up to a total of US$200 million (or the... Read more
New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development Germantown, Maryland, and Hilden, Germany, January 31, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire STAT-Dx, a privately-held company developing... Read more
Solid Q4 results as QIAGEN achieves full-year 2017 targets: Q4 2017: Net sales $396.9 million ( 8% actual, 5% CER); adjusted net sales rise 6% CER excluding portfolio changes vs. 5-6% CER guidance Q4 2017: EPS -$0.18 including impact of predominantly non-cash U.S. tax reform charge; adjusted EPS $0.43 ($0.43 CER) vs. ~$0.41-42 CER guidance... Read more
QIAGEN to conduct an up to $200 million share repurchase program Venlo, The Netherlands, January 31, 2018 – QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has passed a resolution to exercise the authorization granted by the General Meeting of Shareholders on June 21, 2017, and to purchase shares in the... Read more
Germantown, Maryland, and Hilden, Germany, January 18, 2018 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has approved a PMA supplement extending the indications for use of QIAGEN’s therascreen® EGFR RGQ PCR Kit as a companion diagnostic to guide the use of Boehringer Ingelheim’s... Read more
Hilden, Germany, and Germantown, Maryland, January 23, 2018 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a... Read more
Austin, Texas, and Hilden, Germany, November 4, 2015 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the start of commercialization activities for its GeneReader NGS System, the first complete Sample to Insight next-generation sequencing (NGS) solution designed for any laboratory to deliver actionable results. With the introduction of the GeneReader NGS System*,... Read more
Goal set to exceed $140 million of NGS-related sales in 2018, up from over $115 million in 2017 New Enterprise Genomics Services to offer gene panel customization capabilities to customers GeneReader NGS System plans include enhanced chemistry, more powerful gene panels Hilden, Germany, and Germantown, Maryland, January 8, 2018 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt... Read more
Germantown, Maryland, and Hilden, Germany, December 22, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces that, mainly as a consequence of the new U.S. tax legislation, it will take an after-tax charge on net income of approximately $110-120 million (or about $0.47-$0.52 per share) in the fourth quarter of 2017, and an... Read more
QIAGEN to take impairment on deferred tax assets, informs on expected impacts of new U.S. tax law and other changes in global tax environment Germantown, Maryland, and Hilden, Germany, December 22, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces that, mainly as a consequence of the new U.S. tax legislation, it will take... Read more